Clinical trials: Cancer Progression
Fabry Disease
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme.
- Trial name
- NCT00074984
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 82 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, pharmacodynamics (PD), and efficacy of the targeted radionuclide therapeutic CAM-H2 in patients…
- Trial name
- NCT04467515
- Testing
- CAM-H2
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Precirix
Locally Advanced Breast Cancer, Metastatic Breast Cancer
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
- Trial name
- EFECT (NCT00065325)
- Testing
- Fulvestrant, Exemestane
- Where
- 117 sites in United States, Argentina and 13 more
- Volunteers
- 694 people
- Sponsor
- AstraZeneca
Cancer
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
This was a randomized, open-label, multi-center Phase III study evaluating the efficacy and safety of lapatinib in combination with trastuzumab versus trastuzumab alone as continued HER2 suppression therapy in women with…
- Trial name
- NCT00968968
- Testing
- Lapatinib, Trastuzumab
- Where
- 116 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer Metastatic
A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line…
- Trial name
- NCT01703091
- Testing
- Ramucirumab, Docetaxel
- Where
- 15 sites in Japan
- Volunteers
- 197 people
- Sponsor
- Eli Lilly and Company
Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
This is a Natural History study to characterize key aspects of the clinical course of late onset Lysosomal Acid Lipase (LAL) Deficiency/ Cholesteryl Ester Storage Disease (CESD).
- Trial name
- NCT01528917
- Where
- 16 sites in United States, Canada and 6 more
- Volunteers
- 49 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma…
- Trial name
- NCT06943872
- Testing
- Sonrotoclax, Obinutuzumab, Rituximab
- Where
- 195 sites in United States, Argentina and 19 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Melanoma
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.
- Trial name
- LOGIC (NCT01820364)
- Testing
- LGX818
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Array BioPharma
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- DeFineDR (NCT04795726)
- Testing
- Finerenone (BAY94-8862)
- Where
- 11 sites in Bulgaria, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Bayer
CAD - Coronary Artery Disease
REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease
REWRITE-CAD is a prospective, randomized, multi-center trial assessing the management of asymptomatic participants with a history of PCI or MI who will undergo a blinded CCTA and be randomly assigned to either the test arm in…
- Trial name
- REWRITE-CAD (NCT07834372)
- Testing
- Heartflow Analysis
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- HeartFlow, Inc.
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Keratoconus, Corneal Ectasia
Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients
We investigated the use of a copper sulfate eye drop (IVMED-80) for the treatment of keratoconus. Preliminary laboratory data shows that the addition of copper sulfate increase crosslinking of the structural proteins of the…
- Trial name
- NCT05241145
- Testing
- IVMED-80
- Where
- Mexico
- Volunteers
- 38 people
- Sponsor
- iVeena Delivery Systems, Inc.
Treatment for Metastatic or Locally Advanced Cervical Cancer
Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer
This is a single arm open label phase II trial to evaluate the oral daily use of BKM 120 in patients with recurrent unresectable or metastatic cervical cancer after palliative cisplatin based regimen failure.
- Trial name
- NCT01613677
- Testing
- BKM120
- Where
- Brazil
- Sponsor
- Novartis Pharmaceuticals
Non-small Lung Cancer
Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) following Entrectinib progression.
- Trial name
- NCT07199010
- Testing
- Taletrectinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Prostate Cancer
Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer
The purpose of this study is to assess the safety of the second cycle of DCVAC/PCa in patients who completed the first cycle of DCVAC/PCa in the clinical trial SP003 without an objective progression of the disease.
- Trial name
- NCT02137746
- Testing
- Dendritic Cells DCVAC/PCa
- Where
- 7 sites in Czechia
- Volunteers
- 24 people
- Sponsor
- SOTIO a.s.
Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod…
- Trial name
- SWISSMASIA (NCT04895202)
- Testing
- Siponimod
- Where
- 6 sites in Switzerland
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Actinic Keratosis
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream or Solaraze® 3% gel on the face or the scalp.
- Trial name
- LEIDA (NCT00777127)
- Testing
- Imiquimod, Diclofenac
- Where
- 26 sites in Austria, France and 1 more
- Volunteers
- 258 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Secondary Progressive Multiple Sclerosis (SPMS)
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.
- Trial name
- NCT04593927
- Testing
- Mayzent
- Where
- 174 sites in Japan
- Volunteers
- 451 people
- Sponsor
- Novartis Pharmaceuticals
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes).
- Trial name
- OVERTURE (NCT01430494)
- Where
- 266 sites in United States, Argentina and 18 more
- Volunteers
- 3,409 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active…
- Trial name
- NCT00006187
- Testing
- Investigational drug
- Where
- 34 sites in United States
- Sponsor
- Merck Sharp & Dohme LLC